FDA Approves Foundayo: Eli Lilly Launches First Oral GLP-1 Weight Loss Pill
In a historic move for obesity treatment, the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron), a once-daily oral tablet developed by Eli Lilly and Company. This approval marks a significant shift in weight management, offering a non-injectable alternative for adults struggling with obesity or overweight conditions associated with weight-related medical problems.
A Milestone in Regulatory Speed
The approval of Foundayo is not only a victory for patients but too a milestone for the FDA. The drug was approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, which was launched in 2025 to expedite treatments for critical national health priorities.
Foundayo is the first new molecular entity (NME) approved under this program. The efficiency of the process was unprecedented. the FDA issued the decision just 50 days after filing—nearly 300 days ahead of the original PDUFA date of January 20, 2027. According to the FDA, this represents the fastest approval of an NME since 2002.
What is Foundayo and How Does it Work?
Foundayo is a glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike previous GLP-1 medications that require subcutaneous injections, Foundayo is a tablet taken orally once per day. A key advantage of this formulation is its flexibility; it can be taken without restrictions regarding food or water intake.
The medication is approved for use in adults with obesity, or adults who are overweight and have at least one weight-related comorbid condition. To achieve optimal results, the FDA specifies that Foundayo must be used in combination with:
- A reduced-calorie diet
- Increased physical activity
Clinical Efficacy
Data from clinical trials highlight the drug’s potency. At its highest dose, Foundayo delivered an average weight loss of 12.4%, addressing both the clinical needs of patients and the practical challenges of daily medication adherence.
Availability and Access
Eli Lilly is utilizing a multi-channel distribution strategy to bring Foundayo to market quickly. The medication will first be available via LillyDirect, where prescriptions are being accepted immediately. Shipping for these orders is scheduled to begin on April 6, 2026.
Following the initial rollout through LillyDirect, the company expects Foundayo to become broadly available through telehealth providers and retail pharmacies across the United States.
Key Takeaways: Foundayo Approval
- Drug Name: Foundayo (orforglipron)
- Administration: Once-daily oral tablet (no food/water restrictions).
- Primary Use: Weight reduction and maintenance for adults with obesity or overweight with comorbidities.
- Regulatory Path: First NME approved via the CNPV pilot program; fastest NME approval since 2002.
- Clinical Result: Average 12.4% weight loss at the highest dose.
- Availability: Shipping starts April 6 via LillyDirect, followed by retail pharmacies.
Frequently Asked Questions
Who is eligible to take Foundayo?
Foundayo is approved for adults with obesity or adults who are overweight and have at least one weight-related comorbid condition.
Does Foundayo replace diet and exercise?
No. The FDA approval specifies that Foundayo should be used alongside a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain that reduction over the long term.
How is Foundayo different from other GLP-1 drugs?
The primary difference is the delivery method. While many GLP-1s are injectables, Foundayo is a pill that can be taken once daily without the need for needles or strict fasting requirements.
Looking Ahead
The arrival of Foundayo signals a new era of accessibility for GLP-1 therapies. By removing the barrier of injections and leveraging expedited regulatory pathways, Eli Lilly is positioned to expand the reach of obesity medicine. As broad retail availability begins, the focus will shift toward long-term patient outcomes and the integration of oral GLP-1s into standard primary care.